BACKGROUND: Nonsteroidal anti-inflammatory drug (NSAID) use has been associated with a decreased colorectal cancer (CRC) risk. However, to the best of the authors' knowledge, the effects of NSAID on clinical outcomes after CRC diagnosis are not well defined. The authors investigated the association between prediagnosis NSAID use and mortality after CRC diagnosis among women in the California Teachers Study cohort. METHODS: Women aged <85 years participating in the California Teachers Study, without a prior CRC diagnosis at baseline (1995-1996), and who were diagnosed with CRC during follow-up through December 2005, were eligible for analysis of the association between prediagnosis NSAID use and mortality. NSAID use (including aspirin and ibuprofen) was collected through a self-administered questionnaire. Cancer occurrence was identified through California Cancer Registry linkage. Multivariate Cox proportional hazards regression models were used to estimate hazards ratios (HR) for death and 95% confidence intervals (95% CIs). RESULTS: Among 621 CRC patients who were identified, 64% reported no prediagnosis regular NSAID use, 17% reported use of 1 to 6 days/week, and 20% reported daily use. A duration of NSAID use <5 years was reported by 17% of patients and a use of >or=5 years was reported by 18%. Regular prediagnosis NSAID use (1-3 days/week, 4-6 days/week, and daily) versus none was associated with improved overall survival (OS) (HR, 0.71; 95% CI, 0.53-0.95) and CRC-specific survival (HR, 0.58; 95% CI 0.40-0.84) after adjustment for clinically relevant factors. Prediagnosis NSAID use >or=5 years (vs none) was found to be associated with improved OS (HR, 0.55; 95% CI, 0.37-0.84) and CRC-specific survival (HR, 0.40; 95% CI, 0.23-0.71) in adjusted analyses. CONCLUSIONS: When used regularly or over a prolonged duration before CRC diagnosis, NSAIDs are associated with decreased mortality among female CRC patients. Copyright (c) 2009 American Cancer Society.
BACKGROUND: Nonsteroidal anti-inflammatory drug (NSAID) use has been associated with a decreased colorectal cancer (CRC) risk. However, to the best of the authors' knowledge, the effects of NSAID on clinical outcomes after CRC diagnosis are not well defined. The authors investigated the association between prediagnosis NSAID use and mortality after CRC diagnosis among women in the California Teachers Study cohort. METHODS:Women aged <85 years participating in the California Teachers Study, without a prior CRC diagnosis at baseline (1995-1996), and who were diagnosed with CRC during follow-up through December 2005, were eligible for analysis of the association between prediagnosis NSAID use and mortality. NSAID use (including aspirin and ibuprofen) was collected through a self-administered questionnaire. Cancer occurrence was identified through California Cancer Registry linkage. Multivariate Cox proportional hazards regression models were used to estimate hazards ratios (HR) for death and 95% confidence intervals (95% CIs). RESULTS: Among 621 CRC patients who were identified, 64% reported no prediagnosis regular NSAID use, 17% reported use of 1 to 6 days/week, and 20% reported daily use. A duration of NSAID use <5 years was reported by 17% of patients and a use of >or=5 years was reported by 18%. Regular prediagnosis NSAID use (1-3 days/week, 4-6 days/week, and daily) versus none was associated with improved overall survival (OS) (HR, 0.71; 95% CI, 0.53-0.95) and CRC-specific survival (HR, 0.58; 95% CI 0.40-0.84) after adjustment for clinically relevant factors. Prediagnosis NSAID use >or=5 years (vs none) was found to be associated with improved OS (HR, 0.55; 95% CI, 0.37-0.84) and CRC-specific survival (HR, 0.40; 95% CI, 0.23-0.71) in adjusted analyses. CONCLUSIONS: When used regularly or over a prolonged duration before CRC diagnosis, NSAIDs are associated with decreased mortality among female CRC patients. Copyright (c) 2009 American Cancer Society.
Authors: Scott D Solomon; Marc A Pfeffer; John J V McMurray; Rob Fowler; Peter Finn; Bernard Levin; Craig Eagle; Ernest Hawk; Mariajosé Lechuga; Ann G Zauber; Monica M Bertagnolli; Nadir Arber; Janet Wittes Journal: Circulation Date: 2006-09-05 Impact factor: 29.690
Authors: Monica M Bertagnolli; Craig J Eagle; Ann G Zauber; Mark Redston; Scott D Solomon; KyungMann Kim; Jie Tang; Rebecca B Rosenstein; Janet Wittes; Donald Corle; Timothy M Hess; G Mabel Woloj; Frédéric Boisserie; William F Anderson; Jaye L Viner; Donya Bagheri; John Burn; Daniel C Chung; Thomas Dewar; T Raymond Foley; Neville Hoffman; Finlay Macrae; Ronald E Pruitt; John R Saltzman; Bruce Salzberg; Thomas Sylwestrowicz; Gary B Gordon; Ernest T Hawk Journal: N Engl J Med Date: 2006-08-31 Impact factor: 91.245
Authors: Alaa Rostom; Catherine Dubé; Gabriela Lewin; Alexander Tsertsvadze; Nicholas Barrowman; Catherine Code; Margaret Sampson; David Moher Journal: Ann Intern Med Date: 2007-03-06 Impact factor: 25.391
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun Journal: CA Cancer J Clin Date: 2007 Jan-Feb Impact factor: 508.702
Authors: Jason A Zell; Natalia A Ignatenko; Hagit F Yerushalmi; Argyrios Ziogas; David G Besselsen; Eugene W Gerner; Hoda Anton-Culver Journal: Int J Cancer Date: 2007-02-01 Impact factor: 7.396
Authors: Adam J Bass; Jeffrey A Meyerhardt; Jennifer A Chan; Edward L Giovannucci; Charles S Fuchs Journal: Cancer Date: 2008-03-15 Impact factor: 6.860
Authors: Jennifer A Chan; Jeffrey A Meyerhardt; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; James Thomas; Paul Schaefer; Renaud Whittom; Alexander Hantel; Richard M Goldberg; Robert S Warren; Monica Bertagnolli; Charles S Fuchs Journal: JAMA Date: 2008-06-04 Impact factor: 56.272
Authors: Eric J Jacobs; Michael J Thun; Elizabeth B Bain; Carmen Rodriguez; S Jane Henley; Eugenia E Calle Journal: J Natl Cancer Inst Date: 2007-04-18 Impact factor: 13.506
Authors: Xinwei Hua; Amanda I Phipps; Andrea N Burnett-Hartman; Scott V Adams; Sheetal Hardikar; Stacey A Cohen; Jonathan M Kocarnik; Dennis J Ahnen; Noralane M Lindor; John A Baron; Polly A Newcomb Journal: J Clin Oncol Date: 2017-06-15 Impact factor: 44.544
Authors: Michael N Passarelli; Anna E Coghill; Carolyn M Hutter; Yingye Zheng; Karen W Makar; John D Potter; Polly A Newcomb Journal: Genes Chromosomes Cancer Date: 2011-08-24 Impact factor: 5.006
Authors: Anna E Coghill; Polly A Newcomb; Peter T Campbell; Andrea N Burnett-Hartman; Scott V Adams; Elizabeth M Poole; John D Potter; Cornelia M Ulrich Journal: Gut Date: 2010-11-04 Impact factor: 23.059
Authors: Anna E Coghill; Amanda I Phipps; Anthony A Bavry; Jean Wactawski-Wende; Dorothy S Lane; Andrea LaCroix; Polly A Newcomb Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-08-29 Impact factor: 4.254